Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum Toxin A for Depression
NCT00934687Phase 2Completed
- Sponsor
- University Hospital Basel
- Start
- Aug 2009
- Primary completion
- Oct 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
A Phase 2 trial of botulinum toxin type A in major depressive disorder (MDD), sponsored by University Hospital Basel. Started Aug 2009; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00934687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00934687.